Recent Updates
Recently added Catalysts

APG-1387

Phase 1

Chronic Hepatitis B | Small molecule | Infectious Disease |Ascentage Pharma Group International - American Depository Shares|Last Updated: Nov 8, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment49
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03585322APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis BPHASE1 COMPLETED 49 — — Jul 4, 2018Oct 15, 2021Nov 8, 20212 China, China
Unlock Drug Trial Details
Study Design & Arms
AllocationNA
MaskingNONE
PurposeTREATMENT
Interventions
NameTypeDescription
APG-1387 for InjectionDRUGMultiple dose cohorts, 30 minute IV infusion, once weekly for 4 weeks .
Unlock Study Design Details